<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02945813</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 08/15 - PROMET</org_study_id>
    <secondary_id>2016‐003599‐39</secondary_id>
    <nct_id>NCT02945813</nct_id>
  </id_info>
  <brief_title>SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy</brief_title>
  <official_title>SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to explore the efficacy of salvage radiotherapy (SRT) plus
      metformin compared to SRT in the endpoint of time to progression after prostatectomy failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the use of salvage radiotherapy (SRT) is the only potentially curative treatment
      after prostatectomy failure, it has provided suboptimal results over the years. Metformin may
      represent an effective and inexpensive means to improve SRT outcomes with a favorable
      therapeutic ratio. Taken pre-clinical and retrospective clinical data together, there is a
      compelling rationale for conducting a RCT with SRT and metformin. Herein we propose a
      multicenter, randomized, open-label, proof-of-concept phase II trial with the hypothesis that
      the addition of metformin to SRT can delay time to progression compared to the
      standard-of-care SRT. The study has 1:1 randomization and stratification variables include
      Gleason score, PSA at SRT, surgical margin status and ADT use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2017</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>within 18 months after randomization</time_frame>
    <description>The primary endpoint of the trial is time to progression (TTP), defined as time from randomization until one of the following events, whichever comes first:
Biochemical progression
Clinical progression
Death due to clinical progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>within 18 months after randomization</time_frame>
    <description>PFS is defined as time from randomization until one of the following events, whichever comes first:
Biochemical progression
Clinical progression
Death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Undetectable Prostate Specific Antigen (PSA) under normal testosterone levels</measure>
    <time_frame>up to 18 months after last radiotherapy fraction</time_frame>
    <description>Undetectable PSA is defined as a serum PSA value of ≤0.05 ng/mL for at least two consecutive measurements after the last radiotherapy fraction and up to 18 months thereafter. To count as undetectable PSA under normal testosterone levels, the testosterone level has to be ≥50 ng/dL (i.e. a non-castrate testosterone level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% PSA response</measure>
    <time_frame>at randomization up to 18 months after last radiotherapy fraction.</time_frame>
    <description>50% PSA response is defined as a ≥50% PSA decline after radiotherapy compared to the serum PSA level at randomization up to 18 months after last radiotherapy fraction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical progression-free survival</measure>
    <time_frame>week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction.</time_frame>
    <description>Clinical progression-free survival will be calculated as the time from randomization until clinical progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to further anti-cancer systemic therapy</measure>
    <time_frame>week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction.</time_frame>
    <description>Time to further anti-cancer systemic therapy (e.g. hormonal treatment) is defined as the time from randomization to the start of any type of salvage systemic treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer-specific survival (PCSS)</measure>
    <time_frame>at week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction.</time_frame>
    <description>Prostate cancer-specific survival will be calculated as the time from randomization to the date of death due to prostate cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at week 64 then every 6 months for the first year and every 12 months thereafter up to 10 years from last RT fraction.</time_frame>
    <description>Overall survival will be calculated as the time from randomization to the date of death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>until 56 weeks (specific RT-related AEs : until 10 years)</time_frame>
    <description>AEs will be assessed according to NCI CTCAE v4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A: Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin - 850mg PO BID; 48 weeks
Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Salvage Radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- Salvage radiotherapy SRT - 35 x 2Gy; 7 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850mg PO BID; 48 weeks</description>
    <arm_group_label>Arm A: Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Salvage Radiotherapy SRT</intervention_name>
    <description>SRT 35 x 2Gy; 7 weeks</description>
    <arm_group_label>Arm A: Metformin</arm_group_label>
    <arm_group_label>Arm B: Salvage Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to ICH/GCP regulations before registration and
             prior to any trial specific procedures

          -  Histologically confirmed adenocarcinoma of the prostate without small cell features

          -  Tumor stage pT2a-3b, pN0 or cN0, M0, R0-1 resection margins, according to UICC TNM
             2009, Gleason score available

          -  Radical prostatectomy (RP) at least 12 weeks before registration

          -  PSA progression after RP defined as two consecutive rises with the final PSA &gt; 0.1
             ng/mL or three consecutive rises. The first value must be measured earliest 4 weeks
             after RP

          -  PSA ≤ 2 ng/mL within 14 days prior to registration

          -  Age ≥ 18 years at time of registration

          -  WHO performance status 0-1

          -  Adequate hepatic function within 14 days prior to registration: bilirubin ≤ 1.5 x ULN
             (exception if Gilbert's syndrome ≤ 3 x ULN), AST and ALT ≤ 2.5 x ULN

          -  Adequate renal function within 14 days prior to registration: calculated corrected
             creatinine clearance ≥ 60 mL/min, according to the formula of corrected
             Cockcroft-Gault Patient agrees not to father a child and to use effective
             contraceptive methods during salvage radiotherapy and until 6 months after the last
             fraction of radiotherapy

        Exclusion Criteria:

          -  Persistent PSA (&gt; 0.4 ng/mL) 4 to 20 weeks after RP

          -  Pelvic lymph node enlargement &gt; 0.8 cm in short axis diameter (cN positive) assessed
             by mpMRI within 12 weeks prior to registration, unless the enlarged lymph node is
             sampled and negative

          -  Evidence of macroscopic local recurrence assessed by mpMRI within 12 weeks prior to
             registration

          -  Palpable prostatic fossa mass suggestive of recurrence, unless an ultrasound guided
             biopsy is negative for malignancy

          -  Presence or history of prostate cancer metastases. In case of clinical suspicion (e.g.
             bone pain), imaging (e.g. bone scan, Choline-PET, PSMA-PET, whole body MRI) must be
             performed. The imaging method is at the discretion of the investigator.

          -  If PET/CT scan was performed, any metabolic uptake considered clinically suspicious
             for malignancy, unless biopsy proves to be negative.

          -  History of hematologic or primary solid tumor malignancy, unless in remission for at
             least 3 years from registration with the exception of curatively treated localized
             non-melanoma skin cancer

          -  Patients diagnosed with diabetes mellitus

          -  Treatment with metformin within the last 3 months prior to registration

          -  Prior pelvic radiotherapy

          -  Hormonal treatment as bilateral orchiectomy prior or following RP

          -  Usage of products known to affect PSA levels within 4 weeks prior to start of trial
             treatment

          -  Bilateral hip prosthesis

          -  Severe or active co-morbidity likely to impact on the advisability of salvage RT,
             e.g.:

               -  History of inflammatory bowel disease or any malabsorption syndrome or conditions
                  that would interfere with enteral absorption

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months

               -  Transmural myocardial infarction within the last 6 months

               -  Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory
                  illness requiring hospitalization or precluding study therapy at the time of
                  registration

          -  Any condition associated with increased risk of lactic acidosis (e.g. alcohol abuse,
             congestive heart failure NYHA III or IV

          -  Clinically significant history of liver disease consistent with Child-Pugh Class B or
             C, including viral or other hepatitis, current alcohol abuse, or cirrhosis

          -  Severe or uncontrolled kidney disease resulted in impaired kidney function (GFR
             &lt;60ml/min)

          -  Any acute or chronic condition that could cause tissue hypoxia (e.g. cardiac or
             respiratory insufficiency, recent myocardial infarction, shock)

          -  Treatment with any experimental drug or participation within a clinical trial within
             30 days prior to registration (exception: concurrent participation in the biobank
             project SAKK 63/12 is allowed)

          -  Any concomitant drug contraindicated for use with metformin according to the approved
             product information

          -  Known hypersensitivity to metformin/placebo or to any of its components

          -  Hereditary intolerance to fructose; known galactose-1-phosphate uridyl transferase
             deficiency, UDP galactose 4 epimerase deficiency, galactokinase deficiency,
             Fanconi-Bickel syndrome, congenital lactase deficiency, or glucose-galactose
             malabsorption (due to the lactose-containing placebo)

          -  Inability or unwillingness to swallow oral medication

          -  Any other serious underlying medical, psychiatric, psychological, familial or
             geographical condition, which in the judgment of the investigator may interfere with
             the planned staging, treatment and follow-up, affect patient compliance or place the
             patient at high risk from treatment-related complications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel M. Aebersold, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Bern University Hospital - Radiation Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Dal Pra, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Miller School of Medicine, University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniele Oberti, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pirus Ghadjar, MD</last_name>
      <phone>+49 450 657055</phone>
      <email>pirus.ghadjar@charite.de</email>
    </contact>
    <investigator>
      <last_name>Pirus Ghadjar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claus Belka, Prof</last_name>
      <phone>+49 89 4400 74520</phone>
      <email>claus.belka@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Claus Belka, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Rostock</name>
      <address>
        <city>Rostock</city>
        <zip>18059</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Hildebrandt, Prof</last_name>
      <phone>+49 381 494 90 00</phone>
      <email>guido.hildebrandt@uni-rostock.de</email>
    </contact>
    <investigator>
      <last_name>Guido Hildebrandt, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Flentje, Prof</last_name>
      <phone>+49 931 201 288 91</phone>
      <email>flentje_m@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Michael Flentje, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandros Papachristofilou, MD</last_name>
      <phone>+41 61 265 49 46</phone>
      <email>alexandros.papachristofilou@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Alexandros Papachristofilou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana IOSI - Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Che Ngwa Azinwi, MD</last_name>
      <phone>+41 091 811 89 32</phone>
      <email>ngwache.azinwi@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Che Ngwa Azinwi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Aebersold, Prof</last_name>
      <phone>+41 31 632 26 32</phone>
      <email>daniel.aebersold@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel Aebersold, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel R. Zwahlen, MD</last_name>
      <phone>+41 81 256 64 95</phone>
      <email>daniel.zwahlen@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Daniel R. Zwahlen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Genève HUG</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Zilli, MD</last_name>
      <phone>+41 22 372 70 90</phone>
      <email>thomas.zilli@hcuge.ch</email>
    </contact>
    <investigator>
      <last_name>Thomas Zilli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau</name>
      <address>
        <city>Münsterlingen</city>
        <zip>CH-8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Reuter, MD</last_name>
      <phone>+41 71 686 23 33</phone>
      <email>christiane.reuter@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Christiane Reuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Martin Putora, MD</last_name>
      <phone>+41 71 494 22 68</phone>
      <email>paulmartin.putora@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Paul Martin Putora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur KSW</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binaya Kumar Shrestha, MD</last_name>
      <phone>+41 52 266 55 05</phone>
      <email>binayakumar.shrestha@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Binaya Kumar Shrestha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Sumila, MD</last_name>
      <phone>+41 44 387 25 51</phone>
      <email>marcin.sumila@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Marcin Sumila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helmut Kranzbühler, MD</last_name>
      <phone>+41 44 466 13 67</phone>
      <email>helmut.kranzbuehler@triemli.zuerich.ch</email>
    </contact>
    <investigator>
      <last_name>Helmut Kranzbühler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Guckenberger, Prof</last_name>
      <phone>+41 44 255 29 30</phone>
      <email>Matthias.Guckenberger@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Matthias Guckenberger, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2016</study_first_submitted>
  <study_first_submitted_qc>October 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2016</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Prostate Cancer after Prostatectomy</keyword>
  <keyword>Phase II Trial</keyword>
  <keyword>Salvage Radiotherapy</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

